Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0001917
UniProt IDQ9HCD5
Primary gene name(s)NCOA5
Synonym gene name(s)KIAA1637
Protein nameNuclear receptor coactivator 5
Protein functionNuclear receptor coregulator that can have both coactivator and corepressor functions. Interacts with nuclear receptors for steroids, ESR1 and ESR2 independently of the steroid binding domain, AF-2 of the ESR receptors, and with the orphan nuclear receptor NR1D2. Involved in the coactivation of nuclear steroid receptors, ER as well as the corepression of MYC in response to 17-beta-estradiol, E2. {ECO:0000269|PubMed:15073177}.
Subcellular locationNucleus.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: Q9HCD5
Gene Ontology
(Biological Process)
Complete annatation
glucose homeostasis [GO:0042593];
negative regulation of insulin receptor signaling pathway [GO:0046627];
regulation of transcription, DNA-templated [GO:0006355];
signal transduction [GO:0007165];
transcription, DNA-templated [GO:0006351]
Gene Ontology
(Molecular Function)
Complete annatation
chromatin binding [GO:0003682];
poly(A RNA binding [GO:0044822]
Gene Ontology
(Cellular Component)
Complete annatation
actin cytoskeleton [GO:0015629];
extracellular space [GO:0005615];
nucleus [GO:0005634]
Protein-protein interaction121747
Phylogenetic treeQ9HCD5
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
Brass et al., Science, 2008
Smith et al., J. Immunol, 2010
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model

DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD30.3573922849544730.276848431399230.3922778563551
AZA vs. DISU0.1249205891132290.6218669439654970.960057478314726
AZA vs. IL70.06184161112490780.7485778838619960.999311006273513
AZA vs. SAHA-0.5747419202624520.01966724676700370.152737804103974
DISU vs. CD3-0.2449712629299430.5005529755839560.625961137709686
DISU vs. IL7-0.07248771574312770.7737343750982660.94746146281591
DISU vs. SAHA-0.6974360147743510.01768679962161630.14991999836748
DMSO vs. AZA0.006121475765334320.9710093695521471
DMSO vs. CD3-0.3633188382757080.2579413942611330.364963353694568
DMSO vs. DISU-0.1208998017258430.6206491582047420.942122517431912
DMSO vs. IL70.06323571221388680.7260388275555860.944596127159788
DMSO vs. SAHA-0.5861497174813470.01375759349710760.110739044854042
HIV vs. Mock in Activation0.1176550899313650.8499700734333450.999983755607037
HIV vs. Mock in Latency-0.05531092306954630.7390390751775640.999834320637052
IL7 vs. CD3-0.2894089447470670.369657108344360.506991955784763
SAHA vs. CD3-0.9558679246878640.008062390131203130.0214067485490529
SAHA vs. IL7-0.6388761429212750.009342106418240850.0594942594628486
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) FALSE
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK -0.0389337 0.836052
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
0.981 1.099 1.154 1.172 1.161
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

Drugbank ID Drug Name Drug Status Pharmacological Action Drug Action
DB07702 (16ALPHA,17ALPHA)-ESTRA-1,3,5(10)-TRIENE-3,16,17-TRIOL experimental unknown unknown

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
1V95 NMR - A=197-313.
2J7X X-ray 2.1Å B=338-354.
2J7Y X-ray 1.8Å B=338-354.
4ZI1 X-ray 2.1Å B=341-352.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

not found

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
not found